title: [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
abstract: Neuroendocrine small cell carcinoma of the bladder is a rare and aggressive cancer with a very pejorative behavior. Neuroendocrine small cell carcinoma of bladder is a histological entity with special characteristics, rapidly aggressive and metastatic and with a poor prognosis. Because it is rare, there is no consensus to date. Its management should be multidisciplinary, involving surgery, chemotherapy and radiotherapy. We report the case of an 84-year-old patient with neuroendocrine small cell carcinoma of the bladder, treated by neoadjuvant chemotherapy followed by a combined chemoradiotherapy. A review of the literature on this topic is also presented.
authors.affiliation: Département de radiothérapie-oncologie, centre hospitalier Lyon-Sud, chemin du Grand-Revoyet, Pierre-Bénite, France. chekrinetarik@yahoo.fr
authors.forename: T
authors.initials: T
authors.lastname: Chekrine
authors.forename: B
authors.initials: B
authors.lastname: De Bari
authors.forename: P
authors.initials: P
authors.lastname: Cassier
authors.forename: M
authors.initials: M
authors.lastname: Kulisa
authors.forename: O
authors.initials: O
authors.lastname: Chapet
authors.forename: F
authors.initials: F
authors.lastname: Mornex
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D016190:Carboplatin / Q000008:administration & dosage; D002278:Carcinoma in Situ / Q000473:pathology; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000556:secondary; D002295:Carcinoma, Transitional Cell / Q000473:pathology; D003131:Combined Modality Therapy; D004630:Emergencies; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D008297:Male; D020360:Neoadjuvant Therapy; D009378:Neoplasms, Multiple Primary / Q000473:pathology; D011379:Prognosis; D011470:Prostatic Hyperplasia; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use; D019772:Topotecan / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy
chemical_list: D059004:Topoisomerase I Inhibitors; D005047:Etoposide; D019772:Topotecan; D016190:Carboplatin